Last10K.com

Ascendis Pharma As (ASND) SEC Filing 6-K Foreign Issuer Report for the period ending Monday, March 14, 2022

Ascendis Pharma As

HISTORY TOOLS
CIK: 1612042 Ticker: ASND

View differences made from one to another to evaluate Ascendis Pharma As's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 6-K Foreign Issuer Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Ascendis Pharma As.

Continue

Assess how Ascendis Pharma As's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Ascendis Pharma As's Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Material Contracts, Statements, Certifications & more

Ascendis Pharma As provided additional information to their SEC Filing as exhibits

Exhibit 99.1: Additional Exhibits
Ticker: ASND
CIK: 1612042
Form Type: 6-K Foreign Issuer Report
Accession Number: 0001193125-22-074087
Submitted to the SEC: Mon Mar 14 2022 8:01:07 AM EST
Accepted by the SEC: Mon Mar 14 2022
Period: Monday, March 14, 2022
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/asnd/0001193125-22-074087.htm